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Abstract
Background: Disease management programmes (DMPs) have been developed to improve effectiveness and
economic efficiency within chronic care delivery by combining patient-related, professional-directed, and
organisational interventions. The benefits of DMPs within different settings, patient groups, and versions remain
unclear. In this article we propose a protocol to evaluate a range of current DMPs by capturing them in a single
conceptual framework, employing comparable structure, process, and outcome measures, and combining
qualitative and quantitative research methods.
Methods: To assess DMP effectiveness a practical clinical trial will be conducted. Twenty-two disease management
experiments will be studied in various Dutch regions consisting of a variety of collaborations between
organisations and/or professionals. Patient cohorts include those with cardiovascular diseases, chronic obstructive
pulmonary disease, diabetes, stroke, depression, psychotic diseases, and eating disorders. Our methodological
approach combines qualitative and quantitative research methods to enable a comprehensive evaluation of
complex programmes. Process indicators will be collected from health care providers’ data registries and measured
via physician and staff questionnaires. Patient questionnaires include health care experiences, health care utilisation,
and quality of life. Qualitative data will be gathered by means of interviews and document analysis for an in depth
description of project interventions and the contexts in which DMPs are embedded, and an ethnographic process
evaluation in five DMPs. Such a design will provide insight into ongoing DMPs and demonstrate which elements
of the intervention are potentially (cost)-effective for which patient populations. It will also enable sound
comparison of the results of the different programmes.
Discussion: The study will lead to a better understanding of (1) the mechanisms of disease management, (2) the
feasibility, and cost-effectiveness of a disease management approach to improving health care, and (3) the factors
that determine success and failure of DMPs. Our study results will be relevant to decision makers and managers
who confront the challenge of implementing and integrating DMPs into the health care system. Moreover, it will
contribute to the search for methods to evaluate complex healthcare interventions.
Background
Chronic diseases such as cardiovascular diseases (CVD),
diabetes, cancer and respiratory diseases are major
causes of death and disability worldwide and their pre-
valence is expected to rise [1]. They pose a significant
health threat and an increasing challenge to health care
systems. Despite advances in treatment, research shows
that patients often do not receive desirable or necessary
care [2].
The causes of chronic diseases are complex and the
response needs to be multi-faceted [3]. Disease manage-
ment programmes (DMPs) have been developed to
improve effectiveness and economic efficiency of
chronic care delivery [4] by combining patient-related,
professional-directed, and organisational interventions
[5]. The chronic care model (CCM) clusters six
* Correspondence: nieboer@bmg.eur.nl
Institute of Health Policy and Management, Erasmus University Rotterdam, P.
O. Box 1738, 3000 DR Rotterdam, the Netherlands
Lemmens et al. BMC Health Services Research 2011, 11:6
http://www.biomedcentral.com/1472-6963/11/6
© 2011 Lemmens et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
interrelated components of health care systems to trans-
form chronic disease care from acute and reactive to
proactive, planned, and population-based [6]. The effec-
tiveness of multifaceted DMPs is the focus of our study.
Introducing complex, multi-component interventions
is essentially a process of change [7], but description and
explanation of the effects of ongoing DMPs are thus far
inadequate. Improvement in terms of care and costs has
been documented [8,9], but results vary widely across
health care settings, diseases, and target groups. Hetero-
geneity exists in descriptions of interventions and metho-
dological features such as length of follow-up, outcome
measures, and study design [10]. Indeed, the assertion
that results are inconsistent is a typical conclusion from
an experimental design in the area of disease manage-
ment. The effectiveness of these programmes is sensitive
to an array of influences: leadership, changing environ-
ments, details of implementation, organisational history,
financial incentives, and more [11,12]. Although tradi-
tional (quasi-)experimental methods are important for
learning whether improvement interventions change
behaviour, they are ineffective in addressing the crucial
pragmatic (or “realist”) questions about improvement
that stem from its complex social nature: what is it about
the mechanism of a particular intervention that works,
for whom, and under what circumstances [13]? Such
questions call for embracing a wider range of scientific
methodologies. To be valuable for decision making on
local and national levels, evaluation should obtain infor-
mation on both mechanisms (i.e., how specific social pro-
grammes actually produce social changes) and contexts
(i.e., local conditions influencing the outcomes) [5]. In
response, Glasgow et al. [14] have called for the evalua-
tion of DMPs through practical clinical trials conducted
in multiple representative settings, the inclusion of
diverse patient groups, the comparison of alternative ver-
sions of programmes, and employing multiple measures
of relevance to patients, clinicians, and policymakers.
Such practical trials should be accompanied by thorough
and in depth qualitative analysis of organisational and
professional processes in order to explain outcomes.
In the light of the above considerations, the aim of this
study is to evaluate an ongoing national network of
DMPs by capturing them in a single conceptual frame-
work [5] and using similar structure, process, and out-
come measures. The strategy will enable sound
comparison of the different programmes. Differences
between DMPs, in terms of (combinations of) interven-
tions, organisational factors, context, and degree of
implementation are assessed to estimate their indepen-
dent contribution to programme results. Disease-specific
characteristics will be assessed to analyse if they affect
DMPs’ effectiveness. The study will lead to a better
understanding of the mechanisms of disease management
(components) and add to the knowledge about the feasi-
bility and cost-effectiveness of a disease-management
approach to improve health care. The study will also lead
toward identifying factors that determine DMPs’ suc-
cesses or failures. On a meta-level, the study will also
improve our understanding of how to evaluate complex
interventions like DMPs.
Methods
Setting
The study is in the context of a national programme on
“disease management of chronic diseases” carried out by
ZonMw (Netherlands Organisation for Health Research
and Development) and commissioned by the Dutch
Ministry of Health. It will focus on the evaluation of the
implementation of 22 DMPs to enhance knowledge on
disease-management experiments in chronic care, and
stimulate implementation of knowledge and insights of
successful programmes. The DMPs (see Additional file
1) were selected by ZonMw based on quality and rele-
vancy criteria retrieved from their project proposals,
were implemented in various Dutch regions, and com-
prise a variety of collaborations between organisations
and/or professionals (collaborations between general
practices and hospitals, primary care practices (including
physiotherapists and dieticians), or primary and commu-
nity settings). The implementation is financially sup-
ported by ZonMw and DMPs will receive compensation
for participating in the research.
Patient groups
DMPs target different patient populations, including
CVD (9 DMPs), chronic obstructive pulmonary disease
(COPD) (5), diabetes (3), heart failure (1), stroke (1),
depression (1), psychotic diseases (1) and eating disor-
ders (1). To evaluate the effectiveness of DMPs in real-
life settings, we will enrol a broad and representative
sample of patients from each DMP. All patients in the
DMP will be eligible to participate in the evaluation and
no additional inclusion criteria beyond that of the
DMPs will be applied [15]. Written informed consent
will be obtained from all participants.
Ethical approval
The study protocol was approved by the ethics commit-
tee of the Erasmus University Medical Centre of Rotter-
dam (September 2009). All personal identifiers will be
removed or disguised so the person(s) described are not
identifiable and cannot be identified through the details
of the story. All eligible patients will receive a brochure
with research information and an invitation to partici-
pate. The informed consent form makes clear that any
patient can terminate participation in the study at any
time without consequence to quality of usual care.
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Disease management programmes
Each DMP consists of a combination of patient-related,
professional, and organisational interventions (see figure 1).
The exact programme components for each region may
vary. The core of a DMP is described below; for detailed
programme information, see the Additional file 1.
Patient-related interventions
Self-care is critical to optimal management of chronic
diseases. Patients empowered and effective in self-man-
agement are better prepared to positively influence dis-
ease control and health outcomes [16]. Hence, all 22
DMPs include such interventions. Examples of self-man-
agement within the DMPs are patient education on life-
style, motivational interviewing, regulatory skills, and
proactive coping.
Professional-directed interventions
Care standards, guidelines, and protocols are essential
parts of DMPs. They must be integrated through timely
reminders, feedback, and other methods that increase
their visibility at the time that clinical decisions are
made [17]. All DMPs are built on (multidisciplinary)
guidelines. Those directed at CVD will also implement
the CCM; a care standard for diabetes is available. The
implementation strategies for professional interventions
may, however, vary. All DMPs provide training for their
professionals. Implementation of the guideline in 19
DMPs was supported by ICT tools such as integrated
information systems.
Organisational interventions
Effective DMPs require organisational changes. This
often includes organising new collaborations of care
providers, allocating tasks differently, transferring
information and scheduling appointments more
effectively, case management, using new types of health
professionals [5,18], redefining professionals’ roles and
redistributing their tasks, planned interaction between
professionals, and regular follow-up meetings by the
care team. Many forms of organisational changes will be
applied in the 22 regions.
Research methods
The study is a practical clinical trial because it addresses
questions about the risks, benefits, and costs of DMPs
as they would occur in routine clinical practice [15].
Moreover, it combines qualitative and quantitative
research methods [19]. The application of a previously
developed evaluation model will allow us to determine
the relationships between interventions and outcomes
[5]. Such a design will yield empirical evidence on the
effects of the DMPs as well as reveal effective aspects of
the programme and care process changes. Furthermore,
it will give insight in working DMPs and demonstrate
which elements of the intervention are potentially
(cost-) effective. Hence, it will be possible to uncover
opportunities and threats to the implementation of DMPs.
The main comparison will be between DMPs, but most
have a pre-post test design within them. Seven DMPs
have a control group of patients for whom the interven-
tion will be postponed by a period of 1 year (late starters).
General practices (clusters) will be assigned to an early
starter (intervention) group or late starter (control) group
(see figure 2). Two DMPs concerned with eating disor-
ders and stroke will assign patients at random to the
comprehensive DMP or usual care.
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Process evaluation
The effectiveness of a DMP is highly dependent on suc-
cessful implementation, the understanding of which
requires insight into the “black box,” or sequence of
events through which subjects are affected by the inter-
ventions [5]. Glasgow et al. [20] proposed measurement
of contextual factors, intervention implementation, and
behavioural change at both patient and staff levels (see
figure 1). The research question is: “What interventions
are performed within the context of the ‘disease man-
agement in chronic diseases’ programme?”
Process evaluation requires measurement instruments
that are sensitive to specific interventions and connected
to expected changes in outcome data. We will use mul-
tidisciplinary guidelines, care standards, and project pro-
tocols to define process indicators and monitor
programme implementation (see table 1). Data will be
collected from health care providers’ data registries. For
example, we would compare whether actual follow-up
appointments equalled those recommended by the
guidelines.
Process implementation and contextual information
will also be measured by physician and staff question-
naires. The extent to which the care delivered in each
project is consistent with the CCM will be measured
with the Assessment of Chronic Illness Care question-
naire (ACIC) [21]. In projects targeting different dis-
eases, the instrument will enable comparisons. The
questionnaires will also indicate how closely organisa-
tional structures and processes reflect the components
of disease management [12], coordination mechanisms
between organisations and professionals, measures of
leadership and participation, and so on.
Qualitative data will be gathered via interviews with all
22 project leaders and via document analysis for in
depth descriptions of project interventions and the con-
texts in which DMPs are embedded. An ethnographic
design [22] will be used in five DMPs, since ethno-
graphic process evaluations of the implementation of
interventions and their adaptation in practice are neces-
sary to assess the validity and reliability of any interven-
tion effects [23]. Baseline descriptions of the DMPs were
used to select five cases (see Additional file 1) which
reflect variety in regions, patient groups, and interven-
tions. The essence of thick descriptions is to provide a
layered and in depth understanding in order to draw
conclusions and uncover the intentions of the actual
interventions. First, we will seek thick descriptions to (1)
understand how disease management is enacted in prac-
tice [24], (2) gain better understanding of cooperation
between project partners, and (3) reveal possible effects
of contextual factors such as finance and culture. The
qualitative analysis will also focus on how measurements
configure the relations between organisations, profes-
sionals, and professionals/patients because research has
shown the importance of measurements in quality
improvement [25]. Second, within each of the five pro-
jects, ten to fifteen interviews, depending on size and
scope of the project, will be held with project managers,
participating health professionals, and patients. We will
also analyse documents to study regional histories of
integrated care. Third, we will observe project meetings
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to analyse interactions between project partners. Quali-
tative data collection of the five cases will be repeated
several times to analyse project dynamics and changes
over time; after a baseline description at the onset of the
projects, project managers will be interviewed every six
months. A more elaborate round of ethnographic analy-
sis will be done after implementation of the DMPs.
Health outcomes
The aim of the evaluation will be to determine whether
the DMP has achieved the intended effects on processes
and outcome indicators in the intermediate (e.g., lifestyle
and behaviour) and final (clinical parameters, quality of
life (QoL), health care utilisation, and patient experiences)
stages. The research question is, “What are the effects of
DMP on outcomes at the patient, professional, and organi-
sational levels?”
Tunis et al. [15] have called for increased reporting on
outcomes relevant to decision makers, including QoL,
symptom severity, satisfaction, and cost. Table 1 gives a
detailed overview of the outcome measures and instru-
ments. A core set of outcomes will be measured using a
self-administered questionnaire including QoL, health
care utilisation, and patient experiences. We will also
measure disease-specific clinical outcomes (table 1) by
inspecting data from health care providers’ data regis-
tries, preferably electronic ones (e.g., EPD or GP infor-
mation systems (HIS)). We will collaborate closely with
Table 1 Effect evaluation: outcome variables and instruments
Outcomes variables Instruments Items/value
Quality of life
SF-36 Validated questionnaire 36 items
EQ-5D Validated questionnaire 5 items
VAS Validated questionnaire 1 item
HADS Validated questionnaire 14 items
Patient experiences
PACIC Validated questionnaire 20 items
Health care utilisation
Health care utilisation Questionnaire 18 items
Medication utilisation Questionnaire 5 items
Health and Labour (SF-HLQ) Validated questionnaire 7 items
Clinical outcomes
HbA1c (diabetes) Medical registries %
Glucose (diabetes/CVD) Medical registries mmol/l
Blood pressure (diabetes/CVD/heart failure) Medical registries mmHg
Lipids (diabetes/CVD) Medical registries
LDL mmol/l
Total cholesterol mmol/l
FEV1 (COPD) Medical registries %
FEV1/FVC (COPD) Medical registries
Exacerbations (COPD) Medical registries
BDI (depression) Medical registries
Intermediate variables
Smoking/Smoking behaviour Medical registries/Validated questionnaire smoking status 4 items
Physical Activity/SQUASH Medical registries/Validated questionnaire 5 items
Diet Medical registries
SMA-S Validated questionnaire 15 items
Process variables
ACIC Validated questionnaire 34 items
PSAT Validated questionnaire 84 items
Relational Coordination Survey Validated questionnaire 8 items
Motivation of professionals Validated questionnaire 32 items
Process measures (e.g. % patients with care plan) Medical registries %
Notes: SF-36 = Short Form 36; EQ-5D = EuroQol; VAS = Visual Analogue Scale; HADS = Hospital Anxiety and Depression Scale; PACIC = Patient Assessment of
Chronic Illness Care; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease; SMA-S = Self Management Ability Scale; ACIC = Assessment of
Chronic Illness Care; PSAT = Partnership Self-Assessment Tool; SF-HLQ = Short Form-Health and Labour Questionnaire; SQUASH = Short Questionnaire to Assess
Health-Enhancing Physical Activity.
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DMP project leaders and local data managers in collect-
ing data.
Economic evaluation
Cost-effectiveness of DMPs is an important component
of evaluation in lieu of tight health care budgets and
high costs of chronic care. The research question is
“What are the total costs, including those of develop-
ment, implementation, and health care utilisation, asso-
ciated with the interventions; how are they financed and
reimbursed; and how do they relate to the effects of the
interventions?” Each DMP will be subjected to a full
economic evaluation conducted from societal and health
care perspective using the same methodological frame-
work across DMPs.
Costs associated with the development and implemen-
tation of interventions are collected using a standardised
(Excel) format that incorporates costs of health care
professionals, support staff and management, as well as
costs of ICT, training, information and communication,
material, travel, overhead, and so on. These data are
provided by each DMP project leader and finalised by
the HTA-researcher during site visits to each project.
Patient health care utilisation will be collected through
an adapted version of a standardised questionnaire that
concerns contact with care providers, hospital admis-
sions, distance travelled, medication use, and work
absenteeism. The last component enables us to estimate
costs of productivity losses due to illness. In a limited
number of DMPs (see Additional file 1: programmes no.
6, 7, 14, 21, and 22) with severely ill patients, we will
measure the costs of informal care. The sum of the
development and implementation costs plus the costs of
health care utilisation are the total costs of a DMP.
Timing of measurements
Information will be collected at five moments over a
period of two years: intervention baseline (T0) and each
6 months thereafter (T1-T4) until two years after the
start of the DMP (figure 3). At T0, the research team
will collect data from patient records such as lung func-
tion, blood pressure, and lipid values for clinical out-
come and process measurement. A sample of patients
participating in the DMP will receive the first question-
naire from their general practitioners (GPs) to assess
patient history, QoL, health care utilisation and patient
behaviour. At T1 and T3, patients will receive a short
questionnaire to assess health care utilisation only. At
T2 and T4 (end), the team will once more collect data
from patient records and GPs will again issue patients
the questionnaire. Project leaders will provide informa-
tion on the costs of development and implementation of
the DMP at T0, T2, and T4. At the same time points
the professional and staff questionnaires will be
administered. At T0 and T4 qualitative interviews will
be held with all project leaders. Ethnographic data will
be collected throughout the implementation process.
Data analysis
We will explore the effects of DMPs by monitoring their
implementation differences. Descriptive statistical analy-
sis will be performed on patient demographics and
other study variables, such as combinations of interven-
tions or programme implementation. In order to evalu-
ate the costs and effects of the disease management
interventions on the primary outcomes at the patient,
professional and organisational levels, we will compare
changes in outcome measures at T2, T3, and T4
between DMPs and within programmes between inter-
vention and controls. Primary outcomes in terms of
functional status and QoL will be estimated after correc-
tion for potential confounders and differences in starting
values between the treatment groups or projects.
Changes in generic health outcome measures (SF-36,
EQ-5D), number of disease episodes (flare-ups), and
patient experiences will be comparable across projects
with recognition to the fact that the episodes’ nature
and impact varies across diseases. The primary clinical
outcomes (e.g., lung function, cholesterol level) as
extracted from medical records are to some extent
made comparable across projects by expressing them in
number of patients with a ‘minimal clinically important’
improvement.
All data will be analysed according to intention-to-
treat principles in which data from all subjects are used
regardless of the subjects’ adherence to protocol. To
account for missing costs and health outcomes due to
incomplete projects and the uncertainty so introduced,
we will perform sensitivity analyses using various impu-
tation techniques.
The relation between a DMP’s total costs and the esti-
mated health outcome changes is expressed in cost-
effectiveness ratios. Examples are costs (1) per QALY,
(2) per additional patient with a minimal clinically rele-
vant improvement in QoL, (3) per additional patient
with a clinically relevant improvement in the clinical
outcome measure, and (4) per disease episode pre-
vented. Uncertainty around cost-effectiveness will be
dealt with by bootstrapping costs and health outcomes,
plotting them on cost-effectiveness planes, and drawing
cost-effectiveness acceptability curves.
A comprehensive investigation at the individual and
organisational levels requires multi-level analyses, incor-
porating variables at different levels of aggregation to
differentiate between compositional and contextual
effects. Analysis of the outcomes at T1, T2, T3, and T4
will take the dependency of outcomes within patients
into account. Multi-level models will be used to
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distinguish between project- and patient-level effects
[26]. The hierarchical structure of the data gives us the
opportunity to test the effects of the interventions with
respect to structural and process characteristics. Success
and failure factors such as the culture of the participat-
ing organisations and relational coordination (e.g., com-
munication patterns) are likely to relate to the
effectiveness of specific interventions. Multi-level ana-
lyses will enable us to test such contextual effects across
DMPs.
We will analyse the study’s qualitative data - interview
transcripts, project documents, and non-participant
observation notes - with Atlas.ti. We will use open
coding to be alert to issues emerging from the data and
if necessary collect additional data to follow themes.
Coding will be done by two researchers to increase
reliability.
Integration of findings
Methodologically, the assessment of a DMP is the eva-
luation of a complex mixture of interventions at the
patient, professional and organisational levels. Therefore,
qualitative and quantitative methods are mixed through-
out all phases of the project from the design stage
through data collection and interpretation. This enables
understandings of (1) the mechanisms through which
Figure 3 Timeframe of the study.
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DMPs produce change, (2) the contextual conditions
necessary to trigger such mechanisms, and (3) the
effects of DMPs with respect to context and triggered
mechanisms.
Intermediate results of the qualitative, quantitative,
and economic analyses will be continually fed back
within the research group to improve the ‘mixed’ char-
acter of the study, and enable recognition of emerging
themes across research methods and a more fine-
grained analysis of data. This is especially relevant in the
qualitative component of the project. The quantitative
data will be revealed to the qualitative researcher to
allow him or her to tailor the interviews and observa-
tions accordingly. Although each researcher has respon-
sibility for a particular part of the study, regular team
interaction will ensure optimal integration of the results
of the different study parts.
Discussion
The introduction of complex, multi-component inter-
ventions is sensitive to an array of influences such as
details of implementation and context [11,12] and as
such calls for embracing a wide range of scientific meth-
odologies. Although traditional (quasi-)experimental
methods are important to identifying whether improve-
ment interventions have changed care outcomes, they
reveal little about the underlying mechanisms of effec-
tiveness. And, although descriptive studies provide
appropriate understanding of mechanisms and context
of change, they lack rigor in terms of understanding
effectiveness of the intervention. This article thus pre-
sents a methodological approach that combines qualita-
tive and quantitative (mixed) research methods, enabling
a thorough and comprehensive evaluation of complex
programmes.
While improvement of quality of care and cost-effec-
tiveness has been documented in the Netherlands
[27-29], the results vary widely across health care set-
tings, diseases, and target groups. In addition, systematic
reviews pooling evidence from different chronic diseases
[8,9,30] or a single chronic condition (e.g., heart failure,
depression, diabetes, COPD [31-33], [10]) suggest that
DMPs are, to some extent, effective. Indeed, the asser-
tion that DMPs do not work or that results are inconsis-
tent and more research is needed is typical of ill-fitting
research methods. Interpretation is hampered by differ-
ences in the external context of care providers, cultural
aspects, implementation problems, and availability of
resources [7]. The strength of this study’s evaluation
plan is its diversity of tools and perspectives. Moreover,
the application of a theoretical model improves the
design and evaluation of DMPs [5]. Process, intermedi-
ate, and final outcome indicators were selected on theo-
retical grounds. A priori, we expect to find greater
changes in the process and intermediate outcomes
because they are direct DMP targets. Given the current
knowledge on the link between these outcomes and the
health outcomes, it is likely that the latter will improve
too. It may, however, take longer than two years of eva-
luation before the full effects become visible. Extrapolat-
ing results to longer time periods using decision analytic
cost-effectiveness models is an option, provided there is
sufficient information on the association between inter-
mediate and final outcomes.
Some study limitations can be described in advance.
First, given that the nature of DMPs is ‘practical’ and the
level of control is likely to be lower than randomised con-
trolled trials, we anticipate a higher proportion of missing
observations. But the fact that the DMPs are financially
supported to participate and provide data may mitigate
missing values in data collection. Second, this study will
evaluate 22 DMPs, which will generate variation between
programmes. General measures given to each site will
yield a solid evidence base and, in combination with other
data sources such as qualitative descriptions, will lead to
knowledge of DMPs’ effectiveness. Moreover, variation
can be seen as strength, and can be used as an important
source of information. Data collection from multiple set-
tings, diverse patient groups, and alternative programme
versions, and employment of multiple measures will result
in rich data relevant to patients, clinicians, and policy-
makers [7].
In our study a wide range of scientific methodologies
is embraced to evaluate DMPs and obtain information
on both mechanisms and contexts that will be valuable
for decision making on local and national levels. There-
fore, this study will lead to a better understanding of the
mechanisms of DMPs and add to the knowledge on the
feasibility and cost-effectiveness of DMPs in improving
health care. Finally, the study will better highlight the
factors that determine the success and failure of DMPs.
Additional material
Additional file 1: Appendix. 22 disease management programmes.
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